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132 Poster Session-IIeosinophils in bone marrow, gut and peripheral blood were ana-
lysed by using SPSS.
Results: The incidence of acute GvHD was 51% (36% grade 1,
27% grade 2, 15% grade 3 and 22% grade 4 out of it). One organ
aGVHD was diagnosed in 42 (skin n 5 36, gut n 5 4, liver n 5 2),
two-organ aGvHD in 10 and tree-organ aGvHD in 7 patients.
The density of bone marrow eosinophils was increased after RIC-
SCT in comparison to before it (6% vs 3.4%, p\0.001, respectively).
Bone marrow eosinophilia after RIC-SCT was found in 66% of pa-
tients with aGvHD and was a significant predictive factor (p\0.03)
for developing aGvHD. However, eosinophil density did not corre-
lated with aGvHD severity. Peripheral blood eosinophilia was not
predictive for developing aGvHD. Intestinal eosinophils were found
in 15 of 20 patients with clinical signs of gut GvHD, which has been
consequently histologically proven in 13 patients (87%, p\0.02).
The degranulation of eosinophils, determined by using anti-MBP
was present in all patients with gut aGvHD.
Conclusions: Both gastrointestinal tract and bone marrow tissue
eosinophilia after RIC-SCT predict aGvHD. In addition, gut eosin-
ophil density and degranulation were increased in patients with
higher grades of aGvHD thus indicating their role as a biological
marker of GvHD. To our knowledge this is the first study showing
that tissue eosinophil density might be a predictive marker for
aGvHD after RIC-SCT.368
IMMUNOMODULATORY EFFECTS OF VITAMIN D: IMPLICATIONS FOR THE
TREATMENT OF GRAFT VERSUS HOST DISEASE
Rosenblatt, J.1, Bissonnette, A.1, Wu, Z.2, Vasir, B.2, Zarwan, C.1,
Keefe, W.2, Joyce, R.1, Levine, J.D.1, Glotzbecker, B.1, Mills, H.1,
Tzachanis, D.1, Boussiotis, V.1, Kufe, D.2, Avigan, D.1 1 Beth Israel Dea-
coness Medical Center, Boston, MA; 2 Dana Farber Cancer Institute, Bos-
ton, MA
Allogeneic transplantation is uniquely curative for some patients
with hematologic malignancies. However, morbidity and mortality
due to graft versus host disease remain substantial. Persistence of
host dendritic cells (DCs) in the early post transplant period plays
a role in the activation of alloreactive lymphocytes and the risk of
GVHD. A focus of research involves the manipulation of DC re-
covery post-transplant to minimize activation of alloreactive lym-
phocytes while preserving the graft versus disease effect. Vitamin
D is a hormone involved in bone metabolism. More recently, vi-
tamin D has been shown to have immunomodulatory effects. We
evaluated the effect of vitamin D on the phenotypic and functional
characteristics of DC and T cell populations. Peripheral blood
mononuclear cells were isolated from leukopaks obtained from
normal donors. DCs were generated by culturing the monocyte
enriched adherent fraction with GM-CSF and IL-4 for 5 days,
followed by TNFa for 48 hours. DCs were generated in the
presence and absence of 10nM of 1,25 hydroxyvitamin D. Mean
expression of the costimulatory molecule CD80 and the matura-
tion marker CD83 decreased from 60% to 37% and 53% to
27% respectively in the presence of vitamin D (N 5 3). To assess
the effect of vitamin D on the functional potency of DCs as anti-
gen presenting cells, the capacity of DCs to stimulate allogeneic
T cell proliferation in the presence of vitamin D was determined.
Mature DCs were cultured with allogeneic T cells at a ratio of
1:10. After 5 days, cocultures were pulsed with tritiated thymidine
overnight. The addition of vitamin D resulted in a blunted T cell
proliferative response, with mean SI that decreased from 13 to 5
(n 5 10). Similarly, the addition of vitamin D to a coculture of
DCs and autologous T cells resulted in a 50% reduction in the
T cell proliferative response to tetanus toxoid, a recall antigen.
In addition, T cells stimulated by allogeneic DCs in the presence
of vitamin D were polarized to secrete Th2 cytokines. The pres-
ence of vitamin D did not induce FOXP3 expressing regulatory
T cell populations. These data suggest that exposure to vitamin
D exerts a tolerizing influence on T cells mediated by its impact
on antigen presenting cells. Vitamin D may therefore have a role
in the prevention and treatment of graft versus host disease.
A clinical trial evaluating the use of vitamin D in the early post-
transplant period for the prevention of GVHD is planned.369
ALLOGENEIC VERSUS AUTOLOGOUS STEM CELL TRANSPLANTATION
(SCT) FOR FOLLICULAR LYMPHOMA (FL). THE JAMES COMPREHENSIVE
CANCER CENTER EXPERIENCE
Grauer, A.1, Hamadani, M.2, Blum, K.A.2, Porcu, P.2, Benson DM Jr.,
Jr.,2, Devine, S.M.2 1 The Ohio State University; 2 The James Compre-
hensive Cancer Center, The Ohio State University, Columbus, OH
Majority of the reported studies comparing allogeneic versus au-
tologous SCT in patients with FL have short follow-up (median 5
or\5-yrs). Patients with histologically confirmed FL (n 5 117) un-
dergoing SCT between 1985 and 2007 were eligible for this study.
Patient characteristics including age, stage, LDH, number of prior
therapies, remission status at SCT [CR, PR, untreated relapse
(REL), refractory (REF)], and transplant characteristics were re-
corded. The median age was 49 years (range 23–71). 36 patients un-
derwent allogeneic SCT (including 10 patients receiving reduced
intensity conditioning), while 81 patients underwent autologous
SCT.Themedian number of prior treatments for autologous and al-
logeneic SCT groups were 2 (range 1–5) and 3 (range 1–7) respec-
tively. Median follow-up is 7-years. 5-year OS following
autologous SCT for patients in CR1/PR1, CR.1/PR.1 and re-
lapsed or refractory disease was 79%, 71% and 53% respectively.
The respective OS for allogeneic SCTwas 51%, 75%, and 49%. Re-
lapse rates were lower following allogeneic SCT versus autologous
SCT at 27%versus 55% respectively. 5 year progression free survival
(PFS) was higher following allogeneic SCT at 46% versus 38%.
Higher non-relapse mortality (NRM) with allogeneic SCT (25%
versus 11%) resulted in a 5 year OS favoring autologous SCT
(67% versus 57%). With prolonged follow-up a plateau was seen
in allogeneic SCT curve at around 3-yrs, while autologous SCT pa-
tients continued to experience events. Hence the estimates of 10-yr
OS for allogeneic SCT patients was 57% (unchanged from 5-yr
OS), compared to 48% for autologous SCT. Our study shows that
although the early results of allogeneic SCT (mostly withmyeloabla-
tive conditioning) are negatively impacted with associated high
NRM, it produces durable remissions, with eventual appearance of
trends of improved survival with prolonged follow-up.370
PHARMACOKINETICS (PK) OF IV AND PO MYCOPHENOLATE MOFETIL
(MMF) IN AGE ADJUSTED PEDIATRIC AND ADOLESCENT ALLOGENEIC
STEM CELL TRANSPLANT (ALLOSCT) RECIPIENTS: SIGNIFICANTLY
HIGHER CLSS AND VSS IN PATIENTS\6 YEARS OF AGE
Militano, O.1, Bhatia, M.1, Jin, Z.2, Figurski, M.3, Shaw, L.3,
Moore, V.1, Morris, E.1, Tallamy, B.1, van de Ven, C.1, Ayello, J.1,
Baxter-Lowe, L.A.4, Satwani, P.1, George, D.1, Garvin, J.H.1,
Cairo, M.S.1,5,6 1 Morgan Stanley Children’s Hospital New York Presby-
terian, Columbia University, New York, NY; 2 Columbia University, New
York, NY; 3 University of Pennsylvania, Philadelphia, PA; 4 University of
California San Francisco, San Francisco, CA; 5 Morgan Stanley Children’s
Hospital New York Presbyterian, Columbia University, New York, NY;
6 Morgan Stanley Children’s Hospital New York Presbyterian, Columbia
University, New York, NY
Children undergoing AlloSCT exhibit higherMMF dose require-
ments and significant interpatient variability in mycophenolic acid
(MPA) PK (Jacobson P et al, Ped 2008). The objective of this study
is to evaluate effects of age and conditioning intensity on the PK
of MMF in pediatric AlloSCT recipients. From 1/04-5/08 we en-
rolled 38 pts: med age 8 yrs (0.33–16); M:F 5 20:18; 22/16 malig-
nant/non; 17/21 myeloablative (MA)/non-ablative (NMA); 16/22
related/unrelated. Cohort 1 (\6 yrs) n 5 14; 2 (6–12 yrs) n 5 10;
3 (12–16 yrs) n 5 12. GVHD prophylaxis: tacrolimus Day –1 (5–
20 ng/mL) and MMF 900 mg/m2 IV Q6H starting on Day 11,
then converted to PO (same dose) after Day 114. MPA serum sam-
ples were drawn on Days11,17,114 (IV phase) and twice between
Day 145-1100 (PO phase) at hour 0, 0.5, 1, 2, 3, 4, 6 post-dose.
MPA plasma concentrations were determined by reverse-phase
HPLC and LC/MS/MS. Non-compartmental PK analysis of total
MPA was performed. Median time to myeloid and platelet engraft-
ment was 18 and 31 d, respectively. KM probability of Grade II-
IV acute GVHD (aGVHD) and extensive chronic GVHD
Poster Session-II 133(cGVHD) was 54% and 34%, respectively. Probability of OS was
62% (CI95: 48.3–78.4). There was .10-fold interpatient variability
in AUC0-6 and MPA trough (C0). Mean PK are shown in Table 1.
Table 1. Mean pK Parameters
MMF PO MMF POIV MMF administration 1st sample 2nd sampleMean pK
valuesDay 11
(SD) [N527]Day 17
(SD) [N531]Day 114
(SD) [N532]Day 145-100
(SD) [N515]Day 145-100
(SD) [N59]Cmax (mg/L) 15.4 (19.71) 12.31 (7.99)
J 16.54 (13.24)J 13.15 (12.04) 13.20 (8.86)Tmax (h) 1.87 (0.47) 1.92 (0.55) 1.75 (0.44) 1.7 (0.98) 1.33 (0.83)C0 (mg/L) 0.33 (0.29)* 0.68 (0.56)* 0.72 (0.62) 1.45 (1.46) 1.43 (1.37)Css (mg/L) 5.45 (6.34) 4.73 (2.22) 6.46 (4.07) 5.38 (3.55) 6.54 (3.55)AUC0-6
(mgh/L)
32.06 (38.09) 26.82 (12.35)J 33.71 (16.86)J 26.50 (19.03) 26.70 (15.81)CLss (L/hkg) 1.46 (1.04) 1.40 (0.63) * 1.17 (0.63) * 2.21 (1.43) 1.46 (1.01)
Vss (L/kg) 3.04 (1.91) 3.35 (1.58)
l 3.00 (2.05)l 9.77 (8.93) 18.33 (35.74)T1/2 (h) 1.02 (0.69) 1.35 (1.01) 2.49 (6.77) 3.17 (2.63) 10.19 (18.06)*P50.002.
JP50.0003.
lP50.001
MPA steady state clearance (CLss) (cohort 1 vs 2 vs 3 5 1.65 vs
1.45 vs 0.88 L/h$kg, P 5 0.0039) and volume of distribution (Vss)
(cohort 1 vs 2 vs 3 5 3.87 vs 3.22 vs 2.44 L/kg, P 5 0.052) were
higher in pts\6 yrs. There was also a trend toward higher CLss in
pts receiving MA vs NMA (1.55 vs 1.15 L/h$kg, P 5 0.054). There
was a significant difference in most PK values on Day 17 vs Day
114: higher AUC0-6 & Cmax and decreased CLss & Vss on Day
114 (Table 1). These differences suggest improved mucosal healing
and/or increased enterohepatic recirculation on Day 114 vs 17.
Mean MPA Css in this study was significantly higher (.5 mg/L)
than previously reported in other adult and pediatric AlloSCT trials
(1.6–4.8 mg/L) (Nash et al, 2005; Jacobson et al 2008). This can be
explained by .2-fold higher dose of MMF (30 mg/kg q6h) com-
pared to others (15 mg/kg q6-8h). The incidence of aGVHD and
cGVHDwere comparable to previous reports. These results suggest
a need for more frequent (q6h) MMF dosing in pediatric AlloSCT
recipients, especially those\6 years. However, the optimal MMF
dose (mg/kg) and relationship between MPA exposure and risk of
acute GVHD remain to be elucidated.371
HIGH BUDESONIDE BIOAVAILABILITY IN PATIENTS WITH GASTRO-
INTESTINAL (GI) GRAFT VERSUS HOST DISEASE (GVHD) AND/OR
CLOSTRIDIUM DIFFICILE INFECTION
Frame, D.G.1, Markstrom, D.1, Pogue, J.1, Yanik, G.A.2 1 University of
Michigan, Ann Arbor, MI; 2 University of Michigan, Ann Arbor, MI
Background: Therapy of acute intestinal GVHD is routinely
treated with immunosuppressive agents, including systemic cortico-
steroids. Several reports have shown responses of using ‘‘topical’’
therapy with budesonide for GI GVHD. Budesonide is a potent ste-
roid with low oral bioavailability due to high first pass metabolism by
CYP 3A4. In patients with Crohn’s disease, bioavailability is approx-
imately 10–20%. No data are available in hematopoeitic stem cell
transplant recipients. Several reports using budesonide for the treat-
ment of GI GVHD have noted responses in other GVHD sites, thus
questioning if active absorption was occurring. As a quality measure
at our center, several patients who had GI GVHD and/or C. Difficile
were evaluated for systemic availability of budesonide.
Methods: Random plasma budesonide levels were analyzed by
HPLC/Mass Spectrometry in 8 patients with a history of GI
GVHD receiving Enterocort brand of budesonide.
Results: A total of 11 budesonide plasma levels were measured in
8 patients. Seven patients had active GVHD, 5 patients had active
GVHD and concurrent C. Difficile infection, and 2 patients had
C. Difficile without active GVHD at the time of plasma measure-
ments. Four of the 8 levels were measured on a budesonide dose of
9 mg TID, two on 9 mg once daily, three on 6 mg TID, and twoon 3 mg TID. The mean budesonide plasma level was 0.86 mcg/dl
(0.08–1.5), 0.60 mcg/dl (0.09–1.1), 0.97 mcg/dl (0.2 – 1.1) and 0.65
mcg/dl (0.2–1.1) respectively. Mean budesonide levels were higher
if patients were on voriconazole (1.05 mcg/dl) than on micafungin
(0.47 mcg/dl). The mean budesonide bioavailability was 37% in all
patients and 50% if on Voriconazole. Thus, budesonide doses rang-
ing from 3 mg TID to 9 mg TID would represent a potency equiv-
alent to 40–162 mg methylprednisolone/day.
Conclusion: Systemic budesonide levels were significantly ele-
vated in patients with acute GI GVHD. Patients on voriconazole
had higher plasma levels of budesonide, possibly attributable to
CYP450 inhibition. The use of oral budesonide in patients with gas-
tro-intestinal GVHD may lead to systemic absorption and subse-
quent additive systemic corticosteroid effects.IMMUNE RECONSTITUTION372
THYMIC EPITHELIAL CELLS AND DENDRITIC CELLS MEDIATE THYMIC
RENEWAL THROUGH CCL25 PRODUCTION
Williams, K.M., Lucas, P.J., Bare, C.V., Wang, J., Mella, H.A.,
Gress, R.E. National Cancer Institute/NIH, Bethesda, MD
Impaired thymopoiesis contributes to immune deficiency follow-
ing hematopoeitic stem cell transplantation (HSCT). Clinical data
suggest that thymic epithelial cell (TEC) damage from the prepara-
tive regimen may compromise thymic recovery. We have previously
shown that TEC are critical for thymic renewal in the setting of an-
drogen withdrawal. These UEA1 medullary TEC provide a niche
for early thymic progenitor (ETP) entry and thymocyte development
by increasing the production of CCL25. Following androgen with-
drawal, CCL25 accelerates thymocyte development and enhances
ETP entry. Blockade of this ligand completely abrogates these af-
fects, preventing thymic renewal.Wenowdemonstrate that cytotoxic
preparative regimensmay impair thymic reconstitution by damaging
stroma, decreasing CCL25 availability. In this study, we examined
the effects of cyclophosphamide (CY) (240 mg/kg/mouse) or total
body irradiation in female mice on TEC and medullary dendritic
cell (mDC) populations andCCL25 production. At 1⁄2 myeloablative
dose of 750 cGy, usingflow cytometry ofTEC,we show that bothCY
and radiation significantly deplete UEA1 medullary TEC while
sparingLy511CD45- cells. However, the effects of these two agents
differed with regards to the proportions of TEC within the Ly511
fraction. Radiation led to an increase in fibroblasts (CD45- Ly511
MHCII-) with a marked reduction of cortical TEC (CD45- Ly511
MHCII1), while this TEC subset was spared followingCY adminis-
tration. Furthermore, mDC were decreased following radiation
while unaffected by CY. After irradiation, these alterations signifi-
cantly impair CCL25 production as shown by decreasedmRNApro-
duction of TEC enriched preparations and thymocyte fractions (in
which only mDC produce CCL25). In contrast, CCL25 production
was unaffected following CY administration, consistent with the hy-
pothesis that the spared TEC populations preserve CCL25 produc-
tion. These data suggest that cytotoxic preparative regimens may
impair thymic renewal by destroying TEC and mDC populations
thereby reducing available CCL25, a ligand necessary and essential
for thymic recovery. Furthermore, these data suggest that different
preparative regimens may impair thymic recovery to varying degrees
due to discrimination of injuredTEC andmDCpopulations, and the
preservation of thymic CCL25 production. Investigation of alterna-
tive preparative regimen agents may present an opportunity to im-
prove thymic renewal following HSCT.373
HUMAN COLON CARCINOMA CELLS EXPRESSING CMVPP65 ANTIGEN:
AN IN-VIVO MODEL FOR ADOPTIVE IMMUNOTHERAPY OF CMV DISEASE
Hasan, A.N.1, Koo, G.C.1, Selvakumar, A.1, Kollen, W.1, O’Reilly, R.J.1,2
1 Memorial Sloan Kettering Cancer Center, New York, NY; 2 Memorial
Sloan Kettering Cancer Center, New York, NY
Adoptive transfer of large doses of CMV-specific T cells (CMV-
CTL) can effectively prevent CMV disease in HSCT recipients.
However, data regarding the relative potency of T cells (TC) specific
